Display options
Cite
Hey-Hadavi J, Seekins D, Palmer M, et al. Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. Drug Saf. 2021;44(6):619-634doi: 10.1007/s40264-021-01051-5.
Hey-Hadavi, J., Seekins, D., Palmer, M., Coffey, D., Caminis, J., Abdullaev, S., Patwardhan, M., Tyler, H., Raheja, R., Stanley, A. M., Pineda-Salgado, L., Bourdet, D. L., Andrade, R. J., Hayashi, P. H., Dimick-Santos, L., Rockey, D. C., & Estilo, A. (2021). Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. Drug safety, 44(6), 619-634. https://doi.org/10.1007/s40264-021-01051-5
Hey-Hadavi, Juliana, et al. "Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials." Drug safety vol. 44,6 (2021): 619-634. doi: https://doi.org/10.1007/s40264-021-01051-5
Hey-Hadavi J, Seekins D, Palmer M, Coffey D, Caminis J, Abdullaev S, Patwardhan M, Tyler H, Raheja R, Stanley AM, Pineda-Salgado L, Bourdet DL, Andrade RJ, Hayashi PH, Dimick-Santos L, Rockey DC, Estilo A. Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. Drug Saf. 2021 Jun;44(6):619-634. doi: 10.1007/s40264-021-01051-5. Epub 2021 Mar 16. PMID: 33725335; PMCID: PMC8184702.
Copy Download .nbib Format: NLM
Share it on

Drug Saf. 2021 Jun;44(6):619-634. doi: 10.1007/s40264-021-01051-5. Epub 2021 Mar 16.

Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials.

Drug safety

Juliana Hey-Hadavi, Daniel Seekins, Melissa Palmer, Denise Coffey, John Caminis, Sandzhar Abdullaev, Meenal Patwardhan, Haifa Tyler, Ritu Raheja, Ann Marie Stanley, Liliam Pineda-Salgado, David L Bourdet, Raul J Andrade, Paul H Hayashi, Lara Dimick-Santos, Don C Rockey, Alvin Estilo

Affiliations

  1. Pfizer, 235 E 42nd Street, New York City, NY, 10017, USA. [email protected].
  2. Bristol-Myers Squibb, Lawrenceville, NJ, USA.
  3. Takeda, Cambridge, MA, USA.
  4. Liver Consulting LLC, New York City, USA.
  5. Sanofi, Bridgewater, NJ, USA.
  6. AbbVie, North Chicago, IL, USA.
  7. Otsuka Pharmaceutical Development and Commercialization, Inc., 508 Carnegie Center Dr, Princeton, NJ, 08540, USA.
  8. IQ DILI Consortium, Washington, DC, USA.
  9. Theravance Biopharma, South San Francisco, CA, USA.
  10. Unidad de Gestión Clínica de Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Málaga, Spain.
  11. University of North Carolina, Chapel Hill, NC, USA.
  12. US Food and Drug Administration, Silver Spring, MD, USA.
  13. Medical University of South Carolina, Charleston, SC, USA.
  14. Otsuka Pharmaceutical Development and Commercialization, Inc., 508 Carnegie Center Dr, Princeton, NJ, 08540, USA. [email protected].

PMID: 33725335 PMCID: PMC8184702 DOI: 10.1007/s40264-021-01051-5

Abstract

Causality assessment for suspected drug-induced liver injury (DILI) during drug development and following approval is challenging. The IQ DILI Causality Working Group (CWG), in collaboration with academic and regulatory subject matter experts (SMEs), developed this manuscript with the following objectives: (1) understand and describe current practices; (2) evaluate the utility of new tools/methods/practice guidelines; (3) propose a minimal data set needed to assess causality; (4) define best practices; and (5) promote a more structured and universal approach to DILI causality assessment for clinical development. To better understand current practices, the CWG performed a literature review, took a survey of member companies, and collaborated with SMEs. Areas of focus included best practices for causality assessment during clinical development, utility of adjudication committees, and proposals for potential new avenues to improve causality assessment. The survey and literature review provided renewed understanding of the complexity and challenges of DILI causality assessment as well as the use of non-standardized approaches. Potential areas identified for consistency and standardization included role and membership of adjudication committees, standardized minimum dataset, updated assessment tools, and best practices for liver biopsy and rechallenge in the setting of DILI. Adjudication committees comprised of SMEs (i.e., utilizing expert opinion) remain the standard for DILI causality assessment. A variety of working groups continue to make progress in pursuing new tools to assist with DILI causality assessment. The minimum dataset deemed adequate for causality assessment provides a path forward for standardization of data collection in the setting of DILI. Continued progress is necessary to optimize and advance innovative tools necessary for the scientific, pharmaceutical, and regulatory community.

References

  1. Regev A, Seeff LB, Merz M, Ormarsdottir S, Aithal GP, Gallivan J, et al. Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf. 2014;37:47–56. - PubMed
  2. Watkins PB. How to diagnose and exclude drug-induced liver injury. Dig Dis. 2015;33:472–6. - PubMed
  3. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117–26. - PubMed
  4. Hayashi PH. Drug-induced liver injury network causality assessment: criteria and experience in the United States. Int J Mol Sci. 2016;17:201. - PubMed
  5. U.S. Food and Drug Administration (FDA). Guidance for industry drug-induced liver injury: premarketing clinical evaluation. https://www.fda.gov/downloads/guidances/UCM174090.pdf . Accessed 29 Aug 2017. - PubMed
  6. Avigan MI, Bjornsson ES, Pasanen M, Cooper C, Andrade RJ, Watkins PB, et al. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. Drug Saf. 2014;37(Suppl 1):S19-31. - PubMed
  7. Drug-Induced Liver Injury Network (DILIN). 2018. http://www.dilin.org/ . Accessed Apr 2018 - PubMed
  8. Hayashi PH, Barnhart HX, Fontana RJ, Chalasani N, Davern TJ, Talwalkar JA, et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int. 2015;35:1623–32. - PubMed
  9. Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH). Drug Saf. 2011;34:243–52. - PubMed
  10. Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–30. - PubMed
  11. Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, et al. Reliability of the roussel uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology. 2008;48:1175–83. - PubMed
  12. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1):14. - PubMed
  13. Danan G, Teschke R. Drug-induced liver injury: why is the Roussel Uclaf Causality Assessment Method (RUCAM) still in used 25 years after its launch? Drug Saf. 2018;41:735–43. - PubMed
  14. Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS Jr, Alexeeva O, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014;59:1073–83. - PubMed
  15. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331–6. - PubMed
  16. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997;26:664–9. - PubMed
  17. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, De La Cuesta FS. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33:123–30. - PubMed
  18. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-induced liver injury network (DILIN) prospective study. Drug Saf. 2009;32:55–68. - PubMed
  19. Regev A. Drug-induced liver injury and drug development: industry perspective. Semin Liver Dis. 2014;34:227–39. - PubMed
  20. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806–15. - PubMed
  21. Fisher K, Vuppalanchi R, Saxena R. Drug-induced liver injury. Arch Pathol Lab Med. 2015;139:876–87. - PubMed
  22. Andrade RJ, Robles M, Lucena MI. Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opin Drug Saf. 2009;8:709–14. - PubMed
  23. Hunt CM, Papay JI, Stanulovic V, Regev A. Drug rechallenge following drug-induced liver injury. Hepatology. 2017;66:646–54. - PubMed
  24. Teschke R, Danan G. Drug induced liver injury with analysis of alternative causes as confounding variables. Br J Clin Pharmacol. 2018;84:1467–77. - PubMed
  25. Powles T, Bracarda S, Chen M, Norry E, Compton N, Heise M, et al. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients. Eur J Cancer. 2015;51:1293–302. - PubMed
  26. Senior JR. Can rechallenge be done safely after mild or moderate drug-induced liver injury? Hepatology. Drug Saf. 2016;63:691–3. - PubMed
  27. Stanulovic V, Venegoni M, Edwards B. Intentional rechallenge: does the benefit outweigh the risk? Drug Saf. 2013;36:155–61. - PubMed
  28. Sharma SK, Singla R, Sarda P, Mohan A, Makharia G, Jayaswal A, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis. 2010;50:833–9. - PubMed
  29. Tahaoglu K, Atac G, Sevim T, Tarun T, Yazicioglu O, Horzum G, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2001;5:65–9. - PubMed
  30. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002;166:916–9. - PubMed
  31. Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015;63:503–14. - PubMed
  32. Vierling JM. Can study protocols protect patients with liver disease from serious DILI?. In: Presentation at the FDA/critical path annual drug induced liver injury conference XVI. Hyattsville, MD, 2016. - PubMed
  33. National Institutes of Health (NIH). VOTRIENT—pazopanib hydrochloride tablet, film coated. 2016. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eeaaaf38-fb86-4d9f-a19d-0f61daac2fd7 . Accessed July 2018 - PubMed
  34. Chalasani NP, Bonkovsky HL, Fontana RJ, Lee WM, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(1340–52):e7. - PubMed
  35. Regev A, Palmer M, Avigan MI, Dimick-Santos L, Treem WR, Marcinak JF, et al. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2019;49:702–13. - PubMed
  36. Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008;48:1680–9. - PubMed
  37. Zimmerman H. The adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999. - PubMed
  38. Ghabril M, Gu J, Yoder L, Corbito L, Ringel A, Beyer CD, et al. Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury. Gastroenterology. 2019;157(1245–52):e3. - PubMed
  39. U.S. Food and Drug Administration (FDA). Instructions for Completing Form FDA 3500. February 18, 2016. https://www.fda.gov/Safety/MedWatch/%20HowToReport/DownloadForms/ucm149236.htm . Accessed 6 July 2018 - PubMed
  40. D’Incao RB, Silva MC, Almeida PR, Renon VP, Tovo CV. Percutaneous liver biopsy—2 decades of experience in a public hospital in the South of Brazil. Ann Hepatol. 2013;12:876–80. - PubMed
  41. Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2007;15(25):1411–21. - PubMed
  42. Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59:661–70. - PubMed
  43. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–21. - PubMed
  44. Garcia-Cortes M, Stephens C, Lucena MI, Fernandez-Castaner A, Andrade RJ. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol. 2011;55:683–91. - PubMed
  45. Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29:364–72. - PubMed
  46. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22:145–55. - PubMed
  47. Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol. 2009;62(6):481–92. - PubMed
  48. Castiella A, Zapata E, Lucena MI, Andrade RJ. Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. World J Hepatol. 2014;6:160–8. - PubMed
  49. DeLemos AS, Foureau DM, Jacobs C, Ahrens W, Russo MW, Bonkovsky HL. Drug-induced liver injury with autoimmune features. Semin Liver Dis. 2014;34:194–204. - PubMed
  50. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002;6:755–74. - PubMed
  51. Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54(3):931–9. - PubMed
  52. Teschke R, Danan G. Diagnosis and management of drug-induced liver injury (DILI) in patients with pre-existing liver disease. Drug Saf. 2016;39:729–44. - PubMed
  53. Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015;38:1103–13. - PubMed
  54. Agarwal VK, McHutchison JG, Hoofnagle JH, Drug-Induced Liver Injury Network (DILIN). Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8:463–70. - PubMed
  55. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109:950. - PubMed
  56. Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017;66:1154–64. - PubMed
  57. Teschke R, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. World J Gastroenterol. 2013;19:2864–82. - PubMed
  58. Fontana RJ, Seeff LB, Andrade RJ, Bjornsson E, Day CP, Serrano J, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52:730–42. - PubMed
  59. Garcia-Cortes M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ, et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther. 2008;27:780–9. - PubMed
  60. Khan LM, Al-Harthi SE, Osman AM, Sattar MA, Ali AS. Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharm J. 2016;24:485–93. - PubMed
  61. Naidu RP. Causality assessment: a brief insight into practices in pharmaceutical industry. Perspect Clin Res. 2013;4:233–6. - PubMed
  62. Hayashi PH. Overview of causality assessment in drug-induced liver injury. Clin Liver Dis. 2017;9:29–33. - PubMed
  63. Kuepfer L, Kerb R, Henney AM. Clinical translation in the virtual liver network. CPT Pharmacomet Syst Pharmacol. 2014;3:1–4. - PubMed
  64. American Medical Association (AMA). House of Delegates Handbook and Addendum (A-18)—Reference Committee B. https://www.ama-assn.org/sites/default/files/media-browser/public/hod/a18-refcomm-b.pdf#page=64 . Accessed 31 Aug 2018. - PubMed
  65. Gottlieb S. Transforming FDA's Approach to Digital Health. https://www.fda.gov/newsevents/speeches/ucm605697.htm . Accessed 31 Aug 2018. - PubMed
  66. Cheetham TC, Lee J, Hunt CM, Niu F, Reisinger S, Murray R, et al. An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data. Pharmacoepidemiol Drug Saf. 2014;23(6):601–8. - PubMed
  67. Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Caliz I, Gonzalez-Jimenez A, et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147(109–18):e5. - PubMed
  68. U.S. Food and Drug Administration (FDA). Letter of Support Initiative. https://www.fda.gov/drugs/cder-biomarker-qualification-program/letter-support-los-initiative . Accessed 31 Aug 2018. - PubMed
  69. Benesic A, Leitl A, Gerbes AL. Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury. Gut. 2016;65:1555–63. - PubMed
  70. Andrade RJ, Aithal GP, Björnsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, et al. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70:1222–61. - PubMed

Publication Types

Grant support